OnKure (OKUR) CEO makes small 86-share sale to cover RSU taxes

Rhea-AI Filing Summary

OnKure Therapeutics President and CEO Nicholas A. Saccomano reported a small tax-related sale of shares. He sold 86 shares of Class A Common Stock on March 23, 2026 at a weighted average price of $4.1565 per share.

According to the disclosure, these shares were automatically sold to cover tax withholding obligations tied to the vesting of restricted stock units under the company’s 2023 RSU Equity Incentive Plan. After this transaction, he directly holds 7,333 shares of Class A Common Stock.

Insider Trade Summary

Net Seller: 86 shares ($357)

Net Sell 1 txn

Insider Saccomano Nicholas A

Role President and CEO

Sold 86 shs ($357.46)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	86	$4.1565	$357.46

Holdings After Transaction: Class A Common Stock — 7,333 shares (Direct)

Footnotes (1)

1. These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. This transaction was executed in multiple trades at prices ranging from $3.995 to $4.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saccomano Nicholas A

(Last) (First) (Middle)

C/O ONKURE THERAPEUTICS, INC.

6707 WINCHESTER CIRCLE, SUITE 400

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OnKure Therapeutics, Inc. [ OKUR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	03/23/2026		S(1)		86	D	$4.1565(2)	7,333(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.

2. This transaction was executed in multiple trades at prices ranging from $3.995 to $4.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

	/s/ Rogan Nunn, by power of attorney	03/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did OnKure Therapeutics (OKUR) CEO report in this Form 4?

OnKure Therapeutics President and CEO Nicholas A. Saccomano reported selling 86 shares of Class A Common Stock. The shares were sold to cover tax withholding from vesting RSUs under the company’s 2023 RSU Equity Incentive Plan, rather than as a discretionary open-market trade.

How many OnKure (OKUR) shares did the CEO sell and at what price?

Nicholas A. Saccomano sold 86 shares of OnKure Class A Common Stock. The weighted average sale price was about $4.1565 per share, with individual trades executed between $3.995 and $4.235, as detailed in the transaction disclosure and related footnote.

Why were the OnKure (OKUR) CEO’s shares sold in this transaction?

The shares were automatically sold to satisfy tax withholding obligations triggered by the vesting of restricted stock units. This type of transaction is a tax-related mechanism under OnKure’s 2023 RSU Equity Incentive Plan, rather than a voluntary decision to reduce ownership.

How many OnKure (OKUR) shares does the CEO hold after the sale?

Following the tax-related sale, Nicholas A. Saccomano directly holds 7,333 shares of OnKure’s Class A Common Stock. This post-transaction ownership figure is disclosed in the Form 4 and reflects his remaining direct equity stake after the 86 shares were sold.

What do the RSU-related footnotes mean in the OnKure (OKUR) Form 4?

The footnotes explain that some securities are RSUs, each representing a right to one share subject to vesting. They also clarify the sale covered tax withholding from RSU vesting and that trade prices ranged from $3.995 to $4.235, with a weighted average price reported.